The Effect of High Fat Diet on the Pharmacokinetics of AD16 Tablets in Healthy Chinese Adult Subjects

The study was a single-center, randomized, open-access, two-crossover, single-dose study design with 16 subjects to evaluate the pharmacokinetics of a high-fat diet on a single dose of oral AD16 tablets in healthy Chinese adults and the safety of a single dose of oral AD16 tablets in healthy Chinese adults.

Compared with fasting administration, a high-fat diet reduced the rate of AD16 tablet absorption in healthy adult subjects and had no effect on overall exposure to AD16.

The elimination and distribution characteristics of AD16 in vivo were similar under the conditions of feeding and fasting administration.

A single dose of AD16 tablets after fasting and high fat diet showed good safety.

Study Overview

• Status: Completed
• Conditions: Alzheimer Disease
• Intervention / Treatment: Other: high-fat diet group（AD16 20mg）; Other: fasted group（AD16 20mg）

• Study Type: Interventional
• Enrollment (Actual): 16
• Phase: Phase 1

Contacts and Locations

Study Locations

• China
  • Changsha, China
    • The Central South University Xiang Ya Hospital

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 45 years (Adult)
• Accepts Healthy Volunteers: Yes

Description

Inclusion Criteria:

Inclusion Criteria:

1. Healthy subjects were aged 18-45 years (including boundary values), male and female.
2. Weight ≥50kg (male) or ≥45kg (female), and body mass index (BMI) of 19-24kg/m2 (including the boundary values at both ends).
3. Have fully understood this study, voluntarily participated in it, and signed the Informed Consent.
4. Subjects are able to communicate well with researchers and complete the study according to protocol.
5. The subjects were deemed to be in good health based on physical examination, medical history, vital signs, electrocardiogram, chest X-ray, abdominal ultrasound, and laboratory tests.
6. Subject (including partner) is willing to have no pregnancy plan for the next 30 days (female subject) or 90 days (male subject) and is willing to use effective contraception.

Exclusion Criteria:

1. Positive for hepatitis B surface antigen, hepatitis C antibody, syphilis antibody or HIV antibody.
2. The patient has symptoms or related history of any serious disease, including but not limited to heart, liver, kidney, or other acute or chronic digestive tract or respiratory tract diseases, as well as diseases of the blood, endocrine, neurological, psychiatric and other systems, or any other disease or physiological condition that can interfere with the study results.
3. A history of postural hypotension with frequent episodes.
4. A history of frequent nausea or vomiting due to any cause.
5. Any clear history of drug or food allergies, especially allergies to ingredients similar to the drugs in this study.
6. Have special dietary requirements and cannot comply with the uniform diet provided by the clinical research center.
7. Previous drug abuse history or positive urine drug screening during screening period.
8. Smokers who smoked more than 5 cigarettes a day in the 3 months before the test.
9. Heavy drinkers or regular drinkers in the 6 months prior to the study screening, who drank more than 14 units of alcohol per week (1 unit of alcohol ≈360 mL beer or 45 mL 40% spirits or 150 mL wine) or had a positive alcohol breath test during the screening period.
10. Excessive consumption of tea, coffee (more than 6 cups) and/or caffeinated beverages (more than 1L) per day.
11. Take food or drink rich in xanthine, grapefruit or alcohol, caffeine (e.g., dragon fruit, mango, grapefruit, chocolate, coffee or tea) within 48 hours before administration.
12. Surgical procedures, transfusions of blood or blood components in the month prior to study screening.
13. Blood loss or donation of more than 400 mL in the 2 months prior to screening.
14. Participated in other clinical studies and took experimental drugs within 3 months prior to study screening.
15. Study participants who had received any medication in the 28 days prior to screening.
16. Pregnant or lactating women or women who have had unprotected sex within 14 days.
17. Those unable to complete the study for other reasons or deemed unsuitable for inclusion by the researcher.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: High-fat diet group; A single dose of AD16 tablets was taken orally after a high fat diet	Other: high-fat diet group（AD16 20mg）; AD16 was administered with 240 mL water 30 minutes after the subjects ate a high-fat, high-calorie food.
Experimental: Fasting group; A single dose of AD16 tablets was taken orally under fasting conditions	Other: fasted group（AD16 20mg）; Subjects took AD16 on an empty stomach and fasted within 4 hours after taking the drug.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Cmax of AD16	Maximum (peak) plasma drug concentration	Up to Day 10
AUC 0-t of AD16	Area under the plasma concentration-time curve(AUC) from time zero to time t	Up to Day 10
AUC 0-∞ of AD16	Area under the plasma concentration-time curve(AUC) from time zero to infinity	Up to Day 10
t1/2 of AD16	Elimination half-life (to be used in a one-compartment or noncompartmental model)	Up to Day 10
Tmax of AD16	Time to reach the maximum (peak) plasma concentration following drug administration	Up to Day 10
CL/F of AD16	CL/F is defined as the ratio of total clearance(CL) to bioavailability(F).	Up to Day 10
Vd/F of AD16	Apparent volume of distribution after non-intravenous administration	Up to Day 10
MRT of AD16	Mean residence time(MRT)	Up to Day 10
λz of AD16	Terminal disposition rate constant/terminal rate constant	Up to Day 10

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Adverse events	The number of adverse events	day-7 to day 10
Serious adverse events	The number of serious adverse events	day-7 to day 10
Number of participants with abnormal laboratory test results	Laboratory tests include blood routine, blood biochemistry, coagulation function and urine routine	day-7 to day-1 and day10
Number of participants with abnormal vital signs	vital signs include Pulse, blood pressure, body temperature and respiratory rate were observed at different time points before and after medication.	day-7 to day3 and day7 to day10
Number of participants with abnormal 12- Lead ECG readings	abnormal 12- Lead ECG	day-7 to day-1 and days3 、10
Number of participants with abnormal physical examination findings	The skin, mucosa, lymph nodes, head, neck, chest, abdomen, spine/limbs and nervous system were observed at different time points before and after medication.	day-7 to day-1 and day10
Concomitant medication	Any concomitant medication	Up to Day 10

Collaborators and Investigators

• Sponsor: South China Center For Innovative Pharmaceuticals
• Collaborators: Xiangya Hospital of Central South University

Study record dates

Study Major Dates

• Study Start (Actual): June 14, 2019
• Primary Completion (Actual): December 14, 2019
• Study Completion (Actual): December 14, 2019

Study Registration Dates

• First Submitted: March 1, 2023
• First Submitted That Met QC Criteria: March 14, 2023
• First Posted (Actual): March 28, 2023

Study Record Updates

• Last Update Posted (Actual): December 1, 2023
• Last Update Submitted That Met QC Criteria: November 28, 2023
• Last Verified: November 1, 2023

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Mental Disorders; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Neurocognitive Disorders; Neurodegenerative Diseases; Dementia; Tauopathies; Alzheimer Disease
• Other Study ID Numbers: SCCIP-AD16-2018-02

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No